Evidence map›Paper›PMID 36923835›Full record

ArticleHeliyon2023

Kärt Mätlik, Soophie Olfat, Mark Cary Cowlishaw, Eva Domenech Moreno, Saara Ollila, Jaan-Olle Andressoo

Open access · goldAbstract read
In one paragraph

Article in Heliyon, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 2 countries.

Kärt MätlikDepartment of Pharmacology, Faculty of Medicine & Helsinki Institute of Life Science, University of Helsinki, 00290 Helsinki, Finland.
Soophie OlfatDepartment of Pharmacology, Faculty of Medicine & Helsinki Institute of Life Science, University of Helsinki, 00290 Helsinki, Finland.
Mark Cary CowlishawDepartment of Pharmacology, Faculty of Medicine & Helsinki Institute of Life Science, University of Helsinki, 00290 Helsinki, Finland.
Eva Domenech MorenoHelsinki Institute of Life Science, University of Helsinki, 00290 Helsinki, Finland.
Saara OllilaTranslational Cancer Medicine Program, University of Helsinki, 00290 Helsinki, Finland.
Jaan-Olle AndressooDepartment of Pharmacology, Faculty of Medicine & Helsinki Institute of Life Science, University of Helsinki, 00290 Helsinki, Finland.
University of Helsinki · FI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The 3' untranslated regions (UTRs) modulate gene expression levels by regulating mRNA stability and translation. We previously showed that the replacement of the negative regulatory elements from the 3'UTR of glial cell line-derived neurotrophic factor (GDNF) resulted in increased endogenous GDNF expression while retaining its normal spatiotemporal expression pattern. Here, we have developed a methodology for the generation of

Indexed as

3'UTRCRISPR/Cas9GDNFGene functionmicroRNAs

Identifiers

PMID36923835
PMCPMC10009458
OpenAlexW4321766482

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.